10 May 2022 - NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy
AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium.